• Bristol Myers Squibb entered a strategic agreement with Anthropic to deploy its Claude AI platform across research, clinical development, manufacturing, commercial, corporate functions.
• The rollout targets more than 30,000 employees, positioning Claude Enterprise as a shared intelligence layer with agent-based capabilities embedded into core workflows.
• Initial focus includes faster software development using Claude Code, automation of trial documentation to shorten the time from data lock to regulatory filing, improved manufacturing investigations to support batch-release decisions.
• The deployment is designed to connect Claude to internal scientific, clinical, regulatory, commercial repositories through secure integrations with enterprise governance, audit controls.
• The agreement extends a multi-vendor AI approach built on more than three years of internal investment in broad employee access to frontier models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200659BIZWIRE_USPR_____20260520_BW213849) on May 20, 2026, and is solely responsible for the information contained therein.